PBPK modeling predicts higher CBD exposure in many older adults

Predicting Cannabidiol Pharmacokinetics in Older Adults Via Physiologically Based Pharmacokinetic Modeling.

The AAPS journal • • Highly Relevant
🤖

AI Summary

This in vitro and physiologically based pharmacokinetic (PBPK) modeling study examined how CBD is metabolized and whether age changes its expected exposure. The researchers evaluated the roles of cytochrome P450 (CYP) and UGT enzymes, as well as reversible and time-dependent enzyme inhibition. CBD showed time-dependent inhibition only of CYP1A2, and the abstract reports that this had a negligible effect on CBD metabolism. Adding the UGT activators alamethicin and magnesium chloride increased the apparent UGT contribution, potentially overestimating that pathway in laboratory tests.

After comparing model predictions with drug–drug interaction studies, the model best matched observed CBD exposure when metabolism was attributed 86% to CYP enzymes and 14% to UGT enzymes. Simulations generally predicted higher CBD exposure in older adults aged 65–98 years than in younger adults aged 18–64 years, although the difference depended on age and administration route. These findings may help with pharmacokinetic risk assessment, but this was a laboratory-and-modeling study rather than a direct clinical trial in older adults. As an abstract-based summary, it cannot establish how often higher modeled exposure occurs in real-world older people, whether it causes adverse effects, or what dose would be appropriate.

💡 Key Findings

1
The PBPK model best captured observed CBD exposure when metabolism was estimated as 86% CYP-mediated and 14% UGT-mediated.
High
85%
2
CBD showed time-dependent inhibition only of CYP1A2, with a negligible effect on CBD metabolism in the model.
High
80%
3
Including alamethicin plus magnesium chloride increased the apparent UGT contribution and could overestimate UGT-mediated CBD metabolism in laboratory assays.
High
80%
4
Simulations generally predicted increased CBD exposure in adults aged 65–98 years compared with those aged 18–64 years, with the magnitude varying by age and administration route.
Good
75%

📄 Original Abstract

Cannabidiol (CBD) use continues to increase, particularly among older adults. However, knowledge of CBD disposition in this ever-growing and understudied population, along with the relative contributions of cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes to CBD metabolism, remain limited. Inclusion of UGT activators (e.g., alamethicin, MgCl2) may alter in vitro estimates of enzyme contributions. CBD has also been reported to produce time-dependent inhibition (TDI) of certain CYPs, potentially affecting its own disposition. We combined in vitro data with physiologically based pharmacokinetic (PBPK) modeling to further characterize TDI and reversible CYP inhibition by CBD, quantify the contributions of CYPs and UGTs to CBD metabolism, and determine in vitro assay conditions that best reflect in vivo CBD metabolism. PBPK modeling was next used to extrapolate CBD exposure from young (18-64 years) to older (65-98 years) adults. CBD exhibited TDI only toward CYP1A2, which had a negligible effect on CBD metabolism. Inclusion of alamethicin + MgCl2 increased the apparent contribution by UGTs to CBD metabolism, leading to an overestimate of UGT-mediated metabolism. PBPK model validation using drug-drug interaction studies supported contributions of 86% and 14% for CYPs and UGTs, respectively, as best capturing observed CBD exposure. Simulations in older adults generally showed increased CBD exposure relative to young adults, with the magnitude depending on age and administration route. Overall, these results improve our understanding of CBD pharmacokinetics, support more informed risk assessment in older adults, and provide a more robust foundation for future studies.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.